Results of radiotherapy in oropharyngeal carcinomas

Acta Otorrinolaringol Esp (Engl Ed). 2023 May-Jun;74(3):137-147. doi: 10.1016/j.otoeng.2023.05.001. Epub 2023 May 4.

Abstract

Objective: To present the results of radiotherapy treatment in patients with oropharyngeal carcinomas.

Material and methods: Retrospective study of a cohort of 359 patients treated with radiotherapy, including chemo- and bio-radiotherapy, during the period 2000-2019. Information on human papillomavirus (HPV) status was available for 202 patients, of whom 26.2% were HPV-positive.

Results: Five-year local recurrence-free survival was 73.5% (95% CI: 68.8%-78.2%). The variables that were related to local disease control in a multivariate study were the local tumor extension category and the HPV status. Five-year local recurrence-free survival for patients with cT1 tumors was 90.0%, for cT2 88.0%, for cT3 70.6%, and for cT4 42.3%. Five-year local recurrence-free survival for HPV-negative tumors was 67.2% and for HPV-positive tumors 93.3%. Five-year specific-disease survival was 64.4% (95% CI: 59.1%-69.7%). Variables that were related to specific survival in a multivariate study were the patient's general condition, local and regional extent of the tumor, and HPV status.

Conclusions: Five-year local recurrence-free survival of patients with oropharyngeal carcinomas treated with radiotherapy was 73.5%. Variables that were related to local control were local tumor extension and HPV status.

Keywords: Bio-radioterapia; Bio-radiotherapy; Carcinoma de orofaringe; Chemo-radiotherapy; Control local; Local control; Oropharyngeal carcinoma; Quimio-radioterapia; Radioterapia; Radiotherapy; Specific survival; Supervivencia específica.

MeSH terms

  • Carcinoma, Squamous Cell* / pathology
  • Humans
  • Oropharyngeal Neoplasms* / radiotherapy
  • Papillomaviridae
  • Papillomavirus Infections* / complications
  • Retrospective Studies